AURKB and familial pancreatic carcinoma: The choice of chemotherapeutics for the combination experiments was suggested by both their conventional utilisation in cancer chemotherapy and mechanisms of action, interacting with our Aurora B kinase inhibitor, that is, oxaliplatin and gemcitabine in colon and pancreatic cancer in vitro models, respectively.